

Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2009.1.0

Targeted Treatment*



Targeted Treatment

- **Version 2002:**
Schaller / Untch
- **Version 2003–2008:**
**Bischoff / Janni / von Minckwitz / Möbus /
Schaller / Scharl / Schmutzler / Untch**
- **Version 2009:**
Harbeck / Schneeweiss

Further
Information

References

Trastuzumab Treatment in Metastatic Breast Cancer

Oxford / AGO
LoE / GR

Registered in HER-2 positive disease:

- In combination with paclitaxel (1st line)
- In combination with docetaxel (1st line)
- After cytotoxic pretreatment as monotherapy
- As 1st line monotherapy

1b	A	++
1b	A	++
1b	A	++
2b	B	+

Dosage:

- Weekly application
(2 mg/kg i.v., loading dose 4 mg/kg KG)
- 3weekly application
(6 mg/kg i.v., loading dose 8 mg/kg KG)

1b	A	++
2b	C	++

Duration of treatment:

- Start of treatment as early as possible
- Treatment until progression of disease
- Treatment beyond progression

2b	B	++
1b	A	++
2b ^a	C	+

Further
Information

References

Trastuzumab Treatment in Metastatic Breast Cancer

Oxford / AGO
LoE / GR

Treatment in combination with:

➤ Paclitaxel	1b	A	++
➤ Docetaxel	1b	A	++
➤ Paclitaxel / carboplatinum	1b	A	++
➤ Vinorelbine	2b	C	+
➤ Docetaxel/ platinum-complexes	2b	C	+/-
➤ (Peg-)liposomal doxorubicin	2b	C	+
➤ Capecitabine	2b	C	+
➤ Gemcitabine (+/-P, +/- cisplatinum)	2b	C	+
➤ Epirubicin / cyclophosphamide	2b	C	+
➤ Tamoxifen	5	D	+/-
➤ Aromatase inhibitors	2b ^a	C	+

Further
Information

References

Other HER-2 directed therapy

**Oxford / AGO
LoE / GR**

Anthracycline and Taxane and Trastuzumab pre-treatment

Lapatinib + Capecitabine	1c	B	+
Trastuzumab treatment beyond progression	2b ^a	C	+
Trastuzumab + Capecitabine	2b ^a	B	+
Lapatinib + Trastuzumab	2b ^a	B	+/-
Lapatinib + Letrozol	2b ^a	B	+/-

Trastuzumab naive patients: first line therapy

Lapatinib + Paclitaxel	2b	B	+/-
------------------------	----	---	-----

Brain metastases (radioresistance)

Lapatinib (± Capecitabine)	2b	B	+/-
----------------------------	----	---	-----

Further
Information

References

Study Design

© AGO e. V.
in der DGOG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2009.1.0

**HER2+ LABC or
MBC with prior
exposure to an
anthracycline, a
taxane and
trastuzumab***
N=528

Stratification:

- Disease sites
- Stage of disease

R
A
N
D
O
M
I
Z
E

**Lapatinib 1250 mg po qd
continuously +
Capecitabine 2000 mg/m²/d
po days 1-14 q 3 wk**

**Capecitabine 2500 mg/m²/d po
days 1-14 q 3 wk**

Further
Information

References

*Trastuzumab must have been administered for metastatic disease

TBP trial: Capecitabine ± Trastuzumab

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2009.1.0

	C (n = 78)	C H (n = 78)
Response rate	24,6 %	48,9 %
Stable disease	49,1 %	35,1 %
PFS	5,6 months	8,5 months
OS	19,9 months	20,3 months

Further
Information

References

Bevacizumab* Treatment in Metastatic Breast Cancer (HER-2 neg.)

Oxford / AGO
LoE / GR

- **In combination with 1st line paclitaxel (q1w) chemotherapy**

1b	B	+
-----------	----------	----------

- **In combination with 1st line docetaxel (q3w) chemotherapy**

1b^a	B	+
-----------------------	----------	----------

- **In combination with capecitabine chemotherapy***

2b	B	+/-
-----------	----------	------------

Further
Information

References

Metastatic Breast Cancer (HER 2 neg.)

Phase III: Paclitaxel vs. Paclitaxel + Bevacizumab

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2009.1.0

Progression-free Survival (Median)

Paclitaxel	5.9 mo	
Paclitaxel + Bevacizumab	11.8 mo	P<0.001

Further
Information

References